Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.
about
The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trialsIncidence of Neutropenia in Veterans Receiving Lung Cancer Chemotherapy: A Comparison of Administrative Coding and Electronic Laboratory Data.Prophylaxis of chemotherapy-induced febrile neutropenia with granulocyte colony-stimulating factors: where are we now?Neutrophil count in African Americans: lowering the target cutoff to initiate or resume chemotherapy?Dose intensity in early-stage breast cancer: a community practice experienceReversal of chemotherapy-induced leukopenia using granulocyte macrophage colony-stimulating factor promotes bone metastasis that can be blocked with osteoclast inhibitorsNational Cancer Institute Cancer Center designation and 30-day mortality for hospitalized, immunocompromised cancer patientsPredicting individual risk of neutropenic complications in patients receiving cancer chemotherapy.Hodgkin lymphoma treatment with ABVD in the US and the EU: neutropenia occurrence and impaired chemotherapy delivery.Outpatient management following intensive induction or salvage chemotherapy for acute myeloid leukemiaAdvances in the treatment of neutropenia.Development and validation of a prediction model for the risk of developing febrile neutropenia in the first cycle of chemotherapy among elderly patients with breast, lung, colorectal, and prostate cancerImpact of febrile neutropenia on R-CHOP chemotherapy delivery and hospitalizations among patients with diffuse large B-cell lymphomaThe impact of chemotherapy dose intensity and supportive care on the risk of febrile neutropenia in patients with early stage breast cancer: a prospective cohort studyAssessing patients' risk of febrile neutropenia: is there a correlation between physician-assessed risk and model-predicted risk?Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric studyChemotherapy continuity and incidence of febrile neutropenia with CHOP therapy in an outpatient settingRisk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice.COST OF FEBRILE NEUTROPENIA TREATMENT IN BOSNIA AND HERZEGOVINA.Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality.The Emergency Care of Patients With Cancer: Setting the Research Agenda.Compatibility of Biosimilar Filgrastim with Cytotoxic Chemotherapy during the Treatment of Malignant Diseases (VENICE): A Prospective, Multicenter, Non-Interventional, Longitudinal Study.Supportive care in hemato-oncology: a review in light of the latest guidelines.Patterns of chemotherapy-associated toxicity and supportive care in US oncology practice: a nationwide prospective cohort study.Outpatient care of patients with acute myeloid leukemia: Benefits, barriers, and future considerationsProphylactic and therapeutic strategies in chemotherapy-induced neutropenia.Pharmacoeconomics of the myeloid growth factors: a critical and systematic review.Comparative effectiveness of colony-stimulating factors in febrile neutropenia prophylaxis: how results are affected by research design.Risk of chemotherapy-induced neutropenic complications when treating patients with non-Hodgkin lymphoma.The association of hyperglycemia and diabetes mellitus and the risk of chemotherapy-induced neutropenia among cancer patients: A systematic review with meta-analysis.Granulocyte colony-stimulating factors in the prevention of febrile neutropenia: review of cost-effectiveness models.Predicting the risk of chemotherapy toxicity in older patients: the Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score.Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies.Risk factors for bone pain among patients with cancer receiving myelosuppressive chemotherapy and pegfilgrastim.The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum.Incidence, treatment, and consequences of chemotherapy-induced febrile neutropenia in the inpatient and outpatient settings.Costs associated with febrile neutropenia in the US.Colony-stimulating factor use and impact on febrile neutropenia among patients with newly diagnosed breast, colorectal, or non-small cell lung cancer who were receiving chemotherapy.The shape of the myelosuppression time profile is related to the probability of developing neutropenic fever in patients with docetaxel-induced grade IV neutropenia.
P2860
Q27008080-27F7B3E4-CD1D-49AE-90DE-33384D79E731Q33557215-8F6328FA-EA20-454A-B8B3-6190A02F182BQ33756369-B48A031A-DB33-4395-A027-194D0307C021Q33770325-64DE3118-83FF-4469-A16B-8614FB685A4DQ33847958-420A4C19-2060-4657-B9C3-6F590F275EEDQ33926132-609A9AA6-FAFD-41FC-A93C-053D7EFFB9F7Q34005274-8BEB0444-5A02-499E-AE3B-80C24DCDC206Q34026627-F711363E-DD63-4CB0-B84A-79B3FA639036Q34104990-ECF08C8A-A63B-4ADC-B113-92FE5346C63FQ34418965-9BDCCD93-CF55-405A-8BF4-4E53F242CCC2Q34609244-C21E4447-5DF2-4A18-B94D-06D78FF05208Q34613130-A9D32A79-F9A9-45B1-9A8F-186B5EDDEB83Q35730160-F712A430-C68F-4685-AC3E-EC8C4314D36AQ35916166-6C4C2C9D-5105-4CB1-A866-79648A84A458Q36023851-545FCAE6-7F65-46D2-8C60-FC88A5810747Q36723952-5FA9D4BB-C80F-4B63-85E8-C500F5B67D92Q36741541-9D18BC54-06DC-46C5-8918-6A8AC03499F8Q36840636-C57D7F9F-9EA4-4B1C-B0F4-B3F39A7D9390Q36853019-73771FD1-8E8B-41A1-8253-264A03A7B05EQ36885665-528B79E7-5259-43E1-A0C4-E4F9D3841244Q37091111-9B1E28C4-E11F-4007-B7B3-2A7BDBE53F2BQ37211558-A80DD27B-2695-46A1-9896-7C7E69BB1625Q37373201-DED57E9D-E20E-4DEE-A8A7-E4041605EE29Q37702827-6A5E8A87-B2DE-4A4A-B7D1-A3C75EDD761FQ37703409-6FB360FC-7712-4E18-A1CE-A498F783D74FQ37740176-BAD7AD14-40CE-4B8A-811A-D6C0AC2F6A00Q37831314-AAD6DD22-874E-4449-86BA-58F82F293201Q38006021-E45DC214-F4CE-4E1A-A7C8-4B696748AC9CQ38309710-03A33313-BC9D-4A20-BB5D-9ED73F9039EBQ38711166-01EF5549-4FD3-4CC1-AE39-D625B4142852Q38983276-51C5AFA5-16C0-43F1-87FE-D83BFAD1E4CCQ39074316-58347A72-F323-4A6D-AB4D-1DFD7923A5D8Q39688507-695F4F06-A098-4308-93D5-68A643E1DD96Q39698919-2F6C7008-DDFE-46BC-8683-F272F80C9D9DQ40147851-34481D08-BAE2-461D-AC9D-77189DCB06CEQ40222201-909B197C-A17E-48D9-BC8E-0816EB0EF6BFQ40242261-DC07E1ED-5730-4527-93BE-58D0ABA6C426Q40280346-79580A02-50B9-41F0-A631-F69B646E9F9DQ40294108-EC634D3D-5A9F-431F-9FE1-EAAAD1F13BF8Q40306765-BB96C574-8490-4E15-B2F7-FBF60DB03ECF
P2860
Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Risk and timing of neutropenic ...... de study of oncology practice.
@en
type
label
Risk and timing of neutropenic ...... de study of oncology practice.
@en
prefLabel
Risk and timing of neutropenic ...... de study of oncology practice.
@en
P2093
P356
P1476
Risk and timing of neutropenic ...... de study of oncology practice.
@en
P2093
David C Dale
Debra Wolff
Eva Culakova
Gary H Lyman
Jeffrey Crawford
Marek S Poniewierski
Nicole M Kuderer
P304
P356
10.6004/JNCCN.2008.0012
P577
2008-02-01T00:00:00Z